Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bispecific tetravalent antibodies and methods of making and using thereof

A bispecific, binding specificity technology, applied in chemical instruments and methods, antibodies, antibody medical components, etc., can solve the problems of suboptimal and high cost of monoclonal antibodies

Pending Publication Date: 2017-09-26
SYSTIMMUNE INC +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the efficacy of using simple combinations of two or more mAbs is suboptimal
In addition, the cost of producing two or more monoclonal antibodies independently is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific tetravalent antibodies and methods of making and using thereof
  • Bispecific tetravalent antibodies and methods of making and using thereof
  • Bispecific tetravalent antibodies and methods of making and using thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0062] To assess the growth inhibitory potential of anti-HER2 antibodies, the effect on the proliferation of BT-474 cells (ATCC HTB-20, Manassas, Va.), a breast ductal carcinoma tumor cell line, was tested. Cells were seeded into 96-well tissue culture plates at a density of 6000 cells / well with 100 μl RPMI-1640 medium containing 1% fetal calf serum. After 4 hours, the test antibodies were added at different concentrations ranging from 0.0061 nM to 400 nM. Cells were cultured for 7 days in the presence of test antibodies. 20 μl of MTS reagent (Promega, Madison, Wl) was added to each well and the cells were incubated at 37°C for 2 hours. MTS is readily taken up by actively proliferating cells, reduced to formazan (which readily absorbs light at 490 nm), and then secreted into the culture medium. After incubation, OD490 values ​​were measured using a BioTek (Winooski, VT) ELx800 absorbance reader. OD490 values ​​for control cells (treated with medium only) were also obtained ...

example 2

[0065] The ability of anti-Her2 antibodies to be internalized by BT-474 cells was tested. A 1 mg aliquot of antibody standard PBS solution was reacted with Alexa Fluor 488 carboxylic acid, TFP ester (Thermo Fisher #A-10235, Waltham, MA) for 1 hour at room temperature. Unbound dye was removed by gel filtration using a Bio-Gel P-30 column. After conjugation, incubate an aliquot of 3x105 BT-474 cells with 50 nM of each Alexa488-labeled antibody in complete medium (RPMI-1640 + 10% FBS) at 37°C or 4°C (on ice) 1 hour. After incubation, cells were washed twice with ice-cold PBS in a cold centrifuge. Cells were then resuspended in 500 nM quenched rabbit-anti-Alexa488 antibody (Thermo Fisher #A-11094, Waltham, MA) or 500 nM rabbit IgG isotype control antibody (Jackson ImmunoResearch Laboratories #011-000-003, WestGrove, PA ) in either and incubated on ice for 30 minutes. Add two volumes of 2% paraformaldehyde to each sample and incubate for 10 min at room temperature. Cells were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different epitopes on HER2 receptor.

Description

[0001] Cross references to related patent applications [0002] This application claims priority to US Provisional Application No. 62095348, filed December 22, 2014, entitled "BISPECIFIC ANTIBODIES," which is incorporated herein by reference in its entirety. [0003] sequence listing [0004] The Sequence Listing related to this application is provided in text format in lieu of a paper copy and is incorporated into the specification by reference. The text file containing the sequence listing is named Sequence Listing_ST25_0003PCT2.txt. The text file is approximately 164KB, created on December 18, 2015, and submitted electronically via EFS-Web. technical field [0005] The present disclosure relates generally to the technical field of antibodies, and more specifically to bispecific antibodies. Background technique [0006] HER2, a member of the ErbB / HER receptor family, is overexpressed and / or deregulated in several cancers of the breast and ovary (King, Kraus and Aaronson...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395
CPCC07K16/32A61K2039/505C07K2317/35C07K2317/64C07K2317/73C07K2317/732C07K2317/92C07K2317/94A61K47/6849A61K47/6851C07K16/2863C07K2317/31C07K16/3015A61P35/00A61P43/00A61K2039/5152A61K39/3955A61K45/06C07K2317/21C07K2317/24C07K2317/622C07K2317/76A61K39/39558C07K16/468A61K47/6879
Inventor 高泽人朱义菲尔·谭布莱尔·伦肖布莱恩·科瓦切维奇
Owner SYSTIMMUNE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com